Development of an Improved T-cell Assay to Assess the Intrinsic Immunogenicity of Haptenic Compounds.


Journal

Toxicological sciences : an official journal of the Society of Toxicology
ISSN: 1096-0929
Titre abrégé: Toxicol Sci
Pays: United States
ID NLM: 9805461

Informations de publication

Date de publication:
01 06 2020
Historique:
pubmed: 12 3 2020
medline: 16 6 2021
entrez: 12 3 2020
Statut: ppublish

Résumé

The prediction of drug hypersensitivity is difficult due to the lack of appropriate models and known risk factors. In vitro naïve T-cell priming assays that assess immunogenicity have been developed. However, their application is limited due requirements for 2 batches of autologous dendritic cells (DC) and inconsistent results; a consequence of single well readouts when exploring reactions where compound-specific T-cell frequency is undefined. Hence, we aimed to develop an improved, but simplified assay, termed the T-cell multiple well assay (T-MWA), that permits assessment of drug-specific activation of naïve T cells, alongside analysis of the strength of the induced response and the number of cultures that respond. DC naïve T-cell coculture, depleted of regulatory T cells (Tregs), was conducted in up to 48 wells for 2 weeks with model haptens (nitroso sulfamethoxazole [SMX-NO], Bandrowski's base [BB], or piperacillin [PIP]). Cultures were rechallenged with hapten and T-cell proliferation was measured using [3H]-thymidine incorporation. Priming of naïve T cells was observed with SMX-NO, with no requirement for DC during restimulation. Greater than 65% of cultures were activated with SMX-NO; with 8.0%, 30.8%, and 27.2% characterized as weak (stimulation index [SI] =1.5-1.9), moderate (SI = 2-3.9), and strong responses (SI > 4), respectively. The number of responding cultures and strength of the response was reproducible when separate blood donations were compared. Coinhibitory checkpoint blockade increased the strength of the proliferative response, but not the number of responding cultures. Moderate to strong priming responses were detected with BB, whereas PIP stimulated only a small number of cultures to proliferate weakly. In drug-responsive cultures inducible CD4+CD25+FoxP3+CD127low Tregs were also identified. To conclude, the T-MWA offers improvements over existing assays and with development it could be used to study multiple HLA-typed donors in a single plate format.

Identifiants

pubmed: 32159798
pii: 5803091
doi: 10.1093/toxsci/kfaa034
doi:

Substances chimiques

Haptens 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

266-278

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Monday O Ogese (MO)

Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, LiverpoolL69 3GE, UK.

Joel Watkinson (J)

Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, LiverpoolL69 3GE, UK.

Adam Lister (A)

Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, LiverpoolL69 3GE, UK.

Lee Faulkner (L)

Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, LiverpoolL69 3GE, UK.

Andrew Gibson (A)

Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, LiverpoolL69 3GE, UK.
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.

Aimee Hillegas (A)

Immunological Toxicology, In Vitro In Vivo Translation, GlaxoSmithKline, Collegeville, Pennsylvania.

Melanie Z Sakatis (MZ)

Investigative Safety & Drug Metabolism, In Vitro In Vivo Translation, GlaxoSmithKline,HertfordshireSG12 0DP, UK.

Brian Kevin Park (BK)

Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, LiverpoolL69 3GE, UK.

Dean J Naisbitt (DJ)

Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, LiverpoolL69 3GE, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH